MA46024A - Vaccin contre le virus de l'herpès simplex - Google Patents
Vaccin contre le virus de l'herpès simplexInfo
- Publication number
- MA46024A MA46024A MA046024A MA46024A MA46024A MA 46024 A MA46024 A MA 46024A MA 046024 A MA046024 A MA 046024A MA 46024 A MA46024 A MA 46024A MA 46024 A MA46024 A MA 46024A
- Authority
- MA
- Morocco
- Prior art keywords
- herpes simplex
- simplex vaccine
- vaccine
- herpes
- simplex
- Prior art date
Links
- 229940124725 herpes simplex vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245159P | 2015-10-22 | 2015-10-22 | |
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US201562247576P | 2015-10-28 | 2015-10-28 | |
| US201562248252P | 2015-10-29 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46024A true MA46024A (fr) | 2019-07-03 |
Family
ID=58558127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046024A MA46024A (fr) | 2015-10-22 | 2016-10-21 | Vaccin contre le virus de l'herpès simplex |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180303929A1 (enExample) |
| EP (1) | EP3365009A4 (enExample) |
| JP (2) | JP2018536023A (enExample) |
| KR (1) | KR20180096593A (enExample) |
| CN (1) | CN108472355A (enExample) |
| AU (2) | AU2016342049B2 (enExample) |
| BR (1) | BR112018008090A2 (enExample) |
| CA (1) | CA3002822A1 (enExample) |
| CL (1) | CL2018001056A1 (enExample) |
| CO (1) | CO2018005258A2 (enExample) |
| EA (1) | EA201890999A1 (enExample) |
| IL (1) | IL258833A (enExample) |
| MA (1) | MA46024A (enExample) |
| MX (1) | MX2018004918A (enExample) |
| PE (1) | PE20181531A1 (enExample) |
| PH (1) | PH12018500855A1 (enExample) |
| SG (1) | SG11201803365RA (enExample) |
| TN (1) | TN2018000155A1 (enExample) |
| WO (1) | WO2017070623A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| CN115837014A (zh) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| EP3555289A1 (en) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna affinity purification |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170256A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49463A (fr) * | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
| WO2018200613A1 (en) * | 2017-04-26 | 2018-11-01 | Merck Sharp & Dohme Corp. | Hsv antigenic peptides and hsv protein vaccines |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| CA3073161A1 (en) | 2017-08-17 | 2019-02-21 | The Trustees Of The University Of Pennsylvania | Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| EP3999093A4 (en) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | ANTIGENIC E GLYCOPROTEIN POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
| MX2022000879A (es) * | 2019-07-21 | 2022-05-02 | Glaxosmithkline Biologicals Sa | Vacuna viral terapeutica. |
| US12569553B2 (en) | 2020-03-09 | 2026-03-10 | Dynavax Technologies Corporation | Shingles vaccines comprising a TLR9 agonist |
| WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2022006368A2 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| EP4032547A1 (en) * | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022189634A1 (en) * | 2021-03-11 | 2022-09-15 | Redbiotec Ag | Vaccine compositions and methods for treating hsv |
| EP4326227A1 (en) | 2021-04-23 | 2024-02-28 | ModernaTX, Inc. | Stabilized formulations |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250360194A1 (en) | 2021-12-08 | 2025-11-27 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| JP2025508332A (ja) * | 2022-01-27 | 2025-03-26 | ビオンテック エスエー | 単純ヘルペスウイルス抗原の送達のための薬学的組成物及び関連方法 |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| TW202440929A (zh) | 2022-12-14 | 2024-10-16 | 加拿大商普羅維登斯治療控股公司 | 用於感染性疾病的組合物和方法 |
| WO2024131664A1 (zh) * | 2022-12-19 | 2024-06-27 | 南京奥罗生物科技有限公司 | 单纯疱疹病毒疫苗及其应用 |
| JP2026503718A (ja) | 2023-01-30 | 2026-01-29 | モデルナティエックス インコーポレイテッド | エプスタイン・バーウイルスｍＲＮＡワクチン |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024215721A1 (en) | 2023-04-10 | 2024-10-17 | Modernatx, Inc. | Lyme disease vaccines |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| AU2024316307A1 (en) * | 2023-08-03 | 2026-02-26 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2025171082A1 (en) * | 2024-02-06 | 2025-08-14 | Board Of Regents, The University Of Texas System | Prefusion-stabilized hsv2 gb proteins |
| WO2025259931A1 (en) | 2024-06-14 | 2025-12-18 | Orbital Therapeutics, Inc. | Compositions and methods for rna circularization |
| WO2026006203A2 (en) | 2024-06-24 | 2026-01-02 | Orbital Therapeutics, Inc. | Compositions and methods for making circular rna |
| WO2026015882A1 (en) * | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
| WO2026080379A1 (en) | 2024-10-07 | 2026-04-16 | Modernatx, Inc. | Lyme disease mrna vaccines |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1993001301A1 (en) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Mutant antiviral regulatory proteins |
| GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| CA2270282A1 (en) * | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
| US7390780B2 (en) * | 1999-04-23 | 2008-06-24 | Alza Corporation | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification |
| JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
| CN1981873A (zh) * | 2000-06-09 | 2007-06-20 | 莱古伦公司 | 制备微胶粒的方法和所述微胶粒的用途 |
| US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
| CA2462593A1 (en) | 2001-10-03 | 2003-04-10 | Kam W. Leong | Compositions for oral gene therapy and methods of using same |
| AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
| KR101288729B1 (ko) | 2005-04-01 | 2013-07-23 | 인터자인 테크놀로지스, 인코포레이티드 | 약물 전달용 중합체성 마이셀 |
| US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US9149543B2 (en) * | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
| EP2319542B1 (en) | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| US20090304735A1 (en) * | 2006-05-19 | 2009-12-10 | Gabrielle Therese Belz | Immunogenic Compositions |
| US7628993B2 (en) * | 2006-07-20 | 2009-12-08 | Vical Incorporated | Compositions and methods for vaccinating against HSV-2 |
| JP2010502713A (ja) | 2006-09-08 | 2010-01-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液を通る輸送を増強するための組成物および方法 |
| EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
| EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
| WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
| RU2573409C2 (ru) | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
| EP2512459A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME | |
| JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
| EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP2525815B1 (en) | 2010-01-24 | 2015-02-25 | Novartis AG | Irradiated biodegradable polymer microparticles |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
| FI4005592T3 (fi) * | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| KR102266691B1 (ko) * | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| EA201390600A1 (ru) | 2010-10-22 | 2013-09-30 | Байнд Терапьютикс, Инк. | Терапевтические наночастицы с сополимерами с большим молекулярным весом |
| AU2011323250B2 (en) | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| CA2826199A1 (en) * | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
| EP2691078A1 (en) | 2011-03-31 | 2014-02-05 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| ES2820369T3 (es) | 2011-03-31 | 2021-04-20 | Ingell Tech Holding B V | Composiciones biodegradables adecuadas para liberación controlada |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| RU2014104090A (ru) * | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| EP2734184B1 (en) | 2011-07-21 | 2018-03-28 | Croda International Plc | Branched polyether-polyamide block copolymers and methods of making and using the same |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| KR20140067070A (ko) | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질 |
| WO2013044219A1 (en) | 2011-09-22 | 2013-03-28 | Bind Biosciences | Methods of treating cancers with therapeutic nanoparticles |
| US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
| BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| AU2012325997C1 (en) | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| ES2923757T3 (es) * | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| US9415020B2 (en) | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2809702B1 (en) | 2012-02-03 | 2017-12-20 | Rutgers, The State University of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
| WO2013120052A1 (en) | 2012-02-10 | 2013-08-15 | E. I. Du Pont De Nemours And Company | Preparation, purification and use of high-x diblock copolymers |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| WO2014093924A1 (en) * | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| US20150366997A1 (en) * | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| EP3932947A1 (en) * | 2013-03-14 | 2022-01-05 | Translate Bio MA, Inc. | Methods and compositions for delivering mrna coded antibodies |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| ES2967701T3 (es) * | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| HRP20220070T1 (hr) * | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| WO2018226638A1 (en) * | 2017-06-05 | 2018-12-13 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing hsv icp0 protein |
-
2016
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/en active Pending
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko not_active Withdrawn
- 2016-10-21 CA CA3002822A patent/CA3002822A1/en active Pending
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en not_active Ceased
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/en not_active Ceased
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
-
2018
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en not_active Abandoned
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016342049B2 (en) | 2023-05-18 |
| US20180303929A1 (en) | 2018-10-25 |
| TN2018000155A1 (en) | 2019-10-04 |
| AU2023216825A1 (en) | 2023-09-07 |
| US20240173400A1 (en) | 2024-05-30 |
| CO2018005258A2 (es) | 2018-11-22 |
| CA3002822A1 (en) | 2017-04-27 |
| JP2022037134A (ja) | 2022-03-08 |
| PE20181531A1 (es) | 2018-09-26 |
| MX2018004918A (es) | 2019-04-01 |
| BR112018008090A2 (pt) | 2018-11-13 |
| IL258833A (en) | 2018-06-28 |
| JP2018536023A (ja) | 2018-12-06 |
| EA201890999A1 (ru) | 2018-12-28 |
| EP3365009A4 (en) | 2019-07-03 |
| WO2017070623A1 (en) | 2017-04-27 |
| CL2018001056A1 (es) | 2018-10-19 |
| KR20180096593A (ko) | 2018-08-29 |
| SG11201803365RA (en) | 2018-05-30 |
| PH12018500855A1 (en) | 2018-10-29 |
| AU2016342049A1 (en) | 2018-06-07 |
| EP3365009A1 (en) | 2018-08-29 |
| CN108472355A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49463A (fr) | Vaccin contre le virus de l'herpès simplex | |
| EP3365009A4 (en) | VACCINES AGAINST HERPES SIMPLEX VIRUS | |
| EP3364981A4 (en) | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS | |
| MA46584A (fr) | Vaccin contre le cytomégalovirus humain | |
| EP3595713A4 (en) | RESPIRATORY SYNCYTIAL VIRUS Vaccine | |
| MA50813A (fr) | Vaccins contre le virus d'epstein-barr | |
| MA46317A (fr) | Vaccin contre le virus respiratoire syncytial | |
| MA43762A (fr) | Vaccin contre le rsv | |
| MA47016A (fr) | Vaccins contre les virus respiratoires | |
| SG11201803474UA (en) | Vaccines against hepatitis b virus | |
| HUE053078T2 (hu) | Aril-szubsztituált pirimidinek influenza vírus fertõzésben való alkalmazásra | |
| EP3194595A4 (en) | Viral rna segments as immunomodulatory agents and vaccine components | |
| BR112017013009A2 (pt) | formulação de vírus herpes simplex congelada estável | |
| IL253137A0 (en) | Vaccination for foot and mouth disease | |
| DK3355933T3 (da) | Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser | |
| EP3515929A4 (en) | THERAPEUTIC VACCINE AGAINST HEPATITIS B | |
| GB201520345D0 (en) | Herpes simplex viruses | |
| EP3866847A4 (en) | VIRUS VACCINE | |
| DK2941269T3 (da) | Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner | |
| EP3139745B8 (en) | Vaccines against genital herpes simplex infections | |
| IL249539B (en) | Azodicarboxamides containing silicon, their preparation and use | |
| GB201702193D0 (en) | Hepatitis E virus vaccine | |
| EP3706787A4 (en) | VACCINE | |
| EP3383428A4 (en) | VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS | |
| HK1259850A1 (zh) | 单纯疱疹病毒疫苗 |